mild

The SARS-CoV-2 Omicron variant’s “milder” outcomes are likely due to more population immunity rather than the virus’ properties, according to a paper by William Hanage, associate professor of epidemiology at Harvard T.H. Chan School of Public Health, and Roby Bhattacharyya, assistant professor at Massachusetts General Hospital and Harvard Medical School and associate member at the Broad Institute of MIT and